Doximity's Clinical AI Assistant Claims Top U.S. Ranking in Safety Benchmark as Physician Adoption Surges

Doximity announced that its AI clinical assistant "Doximity Ask" achieved top performance among U.S.-based models in the NOHARM benchmark, marking a milestone as the company reports accelerating physician adoption of AI-powered clinical tools. The announcement accompanied first-quarter fiscal 2027 financial results showing revenue growth to $156.6 million but declining profit margins that may signal broader challenges in monetizing clinical AI at scale.

NOHARM Performance and Growing Physician Engagement

Doximity Ask's ranking as the leading U.S.-based model in the NOHARM benchmark positions the company competitively in the clinical AI assistant market, though the source did not provide specific details about the benchmark's methodology or competing models. The achievement comes as the company reports strong adoption metrics across its physician network, with AI Search queries growing more than 25% quarter-over-quarter and workflow-active prescribers increasing by over 30% year-over-year.

The surge in AI tool usage suggests physicians are increasingly integrating AI assistants into daily clinical workflows for information retrieval and decision support. Doximity's network spans more than 85% of U.S. physicians across all specialties, providing a substantial user base for testing and refining clinical AI applications in real-world medical practice settings.

Financial Performance Reveals AI Scaling Economics

Doximity reported first-quarter fiscal 2027 revenue of $156.6 million—up 7% from $145.9 million in the prior-year period—but profitability metrics showed significant compression. Net income fell to $24.3 million (15.5% margin) from $53.3 million (36.5% margin) in the previous year, while adjusted EBITDA declined 6% to $74.8 million (47.7% margin) from $79.8 million (54.7% margin).

The declining margins despite revenue growth and strong user adoption may reflect increased infrastructure costs associated with scaling AI capabilities, a pattern that could have implications for competing platforms developing physician-facing AI tools. The company, founded in 2010 and led by co-founder and CEO Jeff Tangney, provided full-year fiscal 2027 guidance of $671-681 million in revenue and $309-329 million in adjusted EBITDA.

Implications for Clinical AI Competition

Doximity's NOHARM benchmark leadership and physician adoption metrics arrive as the clinical AI assistant market grows increasingly competitive, with established medical reference platforms and emerging AI-focused startups vying for physician attention. The combination of strong user engagement and margin pressure raises questions about the long-term economics of clinical AI tools—whether platforms can maintain financial sustainability while investing in the computational infrastructure and safety validation required for medical applications.

The 30% growth in workflow-active prescribers indicates physicians are finding value in AI-assisted clinical workflows, potentially reshaping how medical professionals access clinical information and make treatment decisions. However, the financial performance suggests that translating physician engagement into profitable business models remains a challenge for health tech companies investing heavily in AI capabilities.

Sources

1. Doximity says its AI assistant was top-performing U.S. model in NOHARM — Stock Titan